Aa
A
A
A
Close
Hepatitis C Community
13.4k Members
Avatar universal

Pegasys vs Peg-Intron

AASLD: HCV Outcomes Found Equivalent With Pegylated Interferons and Ribavirin

"BOSTON, Nov. 4 -- The pegylated interferons alpha-2a (Pegasys) and alpha-2b (PegIntron) are comparably effective and safe in combination with ribavirin (Rebetol) for hepatitis C viral infection, reported investigators here.
Action Points

    * Explain to patients who ask that this study found pegylated interferon in combination with weight-based dosing of ribavirin is effective at controlling or clearing hepatitis C viral infections.

    * Explain that untreated HCV infections can lead to fibrosis, cirrhosis, liver failure and the need for transplant.

    * This study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary as they have not yet been reviewed and published in a peer-reviewed publication.

Although there are no results from head-to-head trials pitting the two pegylagted interferons against each other in combination with ribavirin, a retrospective review showed them similar in efficacy in all patients with HCV infections, reported Ihab Hammoud, M.D., of the Henry Ford Hospital in Detroit, and colleagues.

There were also no significant differences in outcomes or in safety parameters among patients with HCV genotype 1, including those with a high viral load, the investigators reported at the American Association for the Study of Liver Diseases meeting.

The authors looked at all treatment naïve patients with HCV treated with a pegylated interferon and weight-based dose ribavirin at their center from 2001 through 2005. Patients with HCV and HIV or HBV co-infection and those who were on dialysis were excluded from the analysis.

"This was a relatively difficult to treat population," said Dr. Hammoud in an interview. "We had 40% African-American patients, 74% of patients had genotype 1 and 60% had a high viral load, but still we found no real differences between pegylated interferon alpha-2a or pegylated interferon alpha-2b when given with ribavirin with weight-based dosing."

Patients with the more treatment-refractory HCV genotype 1 received peginterferon 2a or 2b and weight-based dose ribavirin for 48 weeks. Patients with HCV genotype 2 or 3 received treatment for either 24 or 48 weeks.

The patients were evaluated for sustained viral responses at 24 weeks with polymerase chain reaction testing for HCV RNA.

A total of 259 patients were included in the analysis, 212 them receiving peginterferon alfa-2b and ribavirin and 47 given peginterferon alfa-2a with ribavirin.

There were no significant differences between the groups in gender, percentage of African-American patients, frequency of HCV genotype, HCV genotype with high viral load, percentage of patients weighing more than 105 kg (231 pounds) or ribavirin dosing.

In addition, on-treatment dose reductions of either peginterferon or ribavirin were similar for the two groups, at 8% for patients on peginterferon-2b and 2% for those on peginterferon-2a (P=NS).

The overall sustained viral response among patients in the 2b group was 38%, and in the 2a groups was 40% (P=NS). Among the patients with genotype 1, the sustained viral response was 23% for patients on 2b, and 26% for patients on 2a (P=NS).

Among patients with genotype 1 and a high viral load, the sustained viral response was 20% for patients on 2b, and 30% for patients on 2a (P=NS), and for those genotype 1 patients who weighed more than 105 kg, the SVR rates were nearly identical, at 20.7% and 20%, respectively (P=NS).

Safety parameters were also similar between the groups, Dr. Hammoud said.

He noted that the study was neither randomized nor controlled, and that the number of patients treated with peginterferon-2b was greater than that of patients treated with peginterfron-2a. The randomized IDEAL trial, conducted by Schering-Plough, maker of PegIntron, compared the two drugs head-to-head. Results are expected later this year or early in 2008."

What struck me was that there was no difference in patients weighing 230+ pounds. I only recently conceded that overweight patients would do better with Peg-Intron than with Pegasys but this study seems to suggest that is not the case. What's your take Jim - am I missing something here?

Mike
15 Responses
223152 tn?1346981971
I think the reason there was no difference between Pegysys and Peg-Intron for patients over 230 is because they did not use weight- based dosing.  My assumption here is that the Peg_intron patients just took the standard dose.  Maybe I am wrong.

Thanks for posting this.
Kathy
Avatar universal
""This was a relatively difficult to treat population," said Dr. Hammoud in an interview. "We had 40% African-American patients, 74% of patients had genotype 1 and 60% had a high viral load, but still we found no real differences between pegylated interferon alpha-2a or pegylated interferon alpha-2b when given with ribavirin with weight-based dosing."

It seems that weight based ribavirin was at play - unless I am confused again.

How have you been lately? I hope your happy and healthy. Mike
Avatar universal
I only recently conceded that overweight patients would do better with Peg-Intron than with Pegasys but this study seems to suggest that is not the case. What's your take Jim - am I missing something here?
---------------------------------------------------
Maybe you conceded too soon. LOL.

But seriously,  as you probably know, many of the top docs seem to have their 'favorite' pegs -- with various reasons, including the one I was given -- none of which were supported by trials and so admitted by the doctors. In my case, I was actually told I might do better on Pegasys, because I was on the lighter side (176 pre-tx) and not sure lighter folks are broken down in this particular study. It also seems intuitive (to me at least) that a 100 pound woman taking 180 peg might do better than a 230 lb man taking 180 peg per week -- given, for example, the double-dose studies, etc. Other than that, really have no other thoughts but thanks for posting.

-- Jim
Avatar universal
It may sound intuitive but my experience is that intuition isn't always correct. When you and I were discussing this a few months ago I did find support for the proposition that Peg-Intron was a better choice for overweight (obese patients) but this seems to contradict that. The only thing that sticks out here is that a significant majority of patients were treated with 2b - 212 while only 47were treated with 2a. If you discount that Pegasys looks as good or better all the way around. The authors also said that the dose reduction between the 2 groups was not significant but 2% vs 8% seems so to me.
Mike
Avatar universal
We'd probably have to look at full-text of both studies to resolve this, and even then, not unusual for studies to differ in conclusions. Perhaps I used the wrong word "intutitive" because I was really basing my view somewhat on the double-dose studies which suggest better results with more peg. I also think 2% and 8% seem significant, but again that might be explained more in the full-text.

-- Jim
Avatar universal
Dr. Cecil seems to think the Pegasus has less side effects. He was the one who convinced me to treat. But I only found out that he preferred Pegasus after I had already started with Peg-Intron because it's weight based. I lost 17 lbs. and was able to cut out one Riba capsule toward the end of tx when I was getting really tired of it all.
Have an Answer?
Top Hepatitis Answerers
317787 tn?1473362051
DC
683231 tn?1467326617
Auburn, WA
Learn About Top Answerers
Didn't find the answer you were looking for?
Ask a question
Answer a few simple questions about your Hep C treatment journey.

Those who qualify may receive up to $100 for their time.
Explore More In Our Hep C Learning Center
image description
Learn about this treatable virus.
image description
Getting tested for this viral infection.
image description
3 key steps to getting on treatment.
image description
4 steps to getting on therapy.
image description
What you need to know about Hep C drugs.
image description
How the drugs might affect you.
image description
These tips may up your chances of a cure.
Popular Resources
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Here’s how your baby’s growing in your body each week.
These common ADD/ADHD myths could already be hurting your child
This article will tell you more about strength training at home, giving you some options that require little to no equipment.
In You Can Prevent a Stroke, Dr. Joshua Yamamoto and Dr. Kristin Thomas help us understand what we can do to prevent a stroke.
Smoking substitute may not provide such a healthy swap, after all.